BI-RADS

At its core, BI-RADS sorts every study into a small set of numbered final assessment categories, conventionally 0 through 6, where each number bundles a level of suspicion with the action it implies — from 'more imaging needed' through 'benign' and 'probably benign' to escalating degrees of cancer concern and, finally, already-proven cancer. The scale is ordered so a higher number broadly signals greater concern or a more definitive next step, and the 'suspicious' tier is further split into low/intermediate/high sub-levels. Separately, the system standardizes how findings are described (shape, margin, density, calcifications, enhancement, breast density). Consult the official ACR BI-RADS v2025 Manual for the exact criteria, definitions, and management language.

• 0 — IncompleteA verdict can't be finalized yet; more imaging or comparison with priors is needed first.
• 1 — NegativeNothing noteworthy to report; routine screening continues.
• 2 — BenignA clearly non-cancerous finding is present; still routine follow-up.
• 3 — Probably benignVery likely harmless, but short-interval surveillance is advised to confirm stability.
• 4 — SuspiciousEnough concern to consider biopsy; spans a wide range and is commonly subdivided 4A/4B/4C.
• 5 — Highly suggestive of malignancyStrong imaging concern for cancer; definitive action expected.
• 6 — Known biopsy-proven malignancyCancer already confirmed pathologically; imaging is tracking known disease.

These are our plain-language summaries. For the exact criteria, thresholds, and management rules, see the official source.

BI-RADS is effectively the universal lexicon for breast imaging, with little real competition — it is the template that later 'RADS' systems (PI-RADS, LI-RADS, and others) were modeled on. In the United States its use is reinforced by federal mammography regulation, which cements its dominance over ad hoc reporting. Where alternatives exist they tend to be complementary rather than rival: automated/volumetric breast-density software, for example, maps its output back onto BI-RADS density classes rather than replacing the framework.

BI-RADS underpins large national audit datasets, and its predictive value rises steeply across the suspicious sub-tiers — reported positive predictive values climb from roughly a third for 4A to the high-80s–90s percent for 4B/4C and category 5 — which validates the stratification while exposing that sub-categorizing category 4 is subjective and reader-dependent. Inter-reader reproducibility is generally substantial but imperfect, with breast-density assignment in particular showing meaningful variability between editions and experience levels. Historical analyses credit BI-RADS with materially reducing reporting ambiguity and enabling outcomes monitoring since the 1990s. Recurring criticisms — interpretive variability in the probably-benign and suspicious zones, and density-assessment subjectivity — are explicitly among the issues the 2025 6th edition set out to address.

What does a BI-RADS category actually tell me?

It combines how suspicious a finding looks with what should happen next — the same number signals both a level of concern and a recommended action (routine screening, short-interval follow-up, biopsy, and so on).

Is BI-RADS 3 cancer?

No. Category 3 means a finding is very likely benign, with only a small chance of cancer, so the usual advice is a short-interval follow-up scan to confirm stability rather than an immediate biopsy.

Why is category 4 split into 4A, 4B, and 4C?

Because 'suspicious' covers a very wide probability range. The sub-levels separate low-concern from high-concern findings so the chance of cancer — and the urgency — is communicated more precisely.

What's new in the 2025 (6th) edition?

It is the biggest update in over a decade: mandatory standalone breast-density reporting, tomosynthesis and contrast-enhanced mammography fully integrated, modernized ultrasound and MRI vocabularies, clarified categories 0 and 6, and a rename from 'Atlas' to 'Manual.'

Did the 0–6 categories change in 2025?

The overall numbered scheme was kept; the changes were clarifications (notably to categories 0 and 6) and modernized descriptors, not a renumbering of the scale.

Who maintains BI-RADS, and is it free?

The American College of Radiology maintains it. The landing pages and 'what's new' summaries are public, but the full v2025 Manual is a paid ACR publication.

Assessment category

The final numbered conclusion (0–6) pairing a suspicion level with a management recommendation.

Lexicon

The agreed set of standardized terms used to describe imaging findings (shape, margin, calcifications, enhancement).

Breast density

A graded description of how much fibroglandular tissue is present, affecting both cancer risk and how well mammography can detect disease.

DBT (digital breast tomosynthesis)

'3D' mammography that acquires thin image slices to reduce overlapping-tissue confusion.

CEM (contrast-enhanced mammography)

Mammography after iodinated contrast to highlight areas of abnormal blood flow; elevated to a core modality in v2025.

NME (non-mass enhancement)

An MRI pattern of enhancement that doesn't form a discrete mass; v2025 adds an analogous 'non-mass' concept to ultrasound.

MQSA

The U.S. Mammography Quality Standards Act, the federal regulation tying mammography reporting to standardized assessment language.

• officialACR BI-RADS official page
• officialACR announcement — BI-RADS v2025 Manual released
• referenceRadiology Assistant — BI-RADS educational reference
• patientBreast-cancer.ca — BI-RADS categories (patient explainer)